GenEvolutioN at EUROTOX 2025: advancing non-animal genotoxicity testing for cosmetics
On September 14th, 2025, GenEvolutioN will take part in EUROTOX 2025 in Athens, sharing its cutting-edge research on the Reconstructed Skin Micronucleus (RSMN) assay—a promising tool for evaluating genotoxic risks in cosmetic products.
New approach methodologies: from ethics to scientific relevance
Driven by the New Approach Methodologies (NAMs) movement, GenEvolutioN leverages human-relevant in vitro models to replace animal testing. The RSMN assay, using the 3D reconstructed EpiDerm™ skin model, offers a physiologically relevant system that mimics human skin, accounting for dermal absorption, metabolism, and cell interactions.
This approach enhances the predictive value of genotoxicity testing, particularly when standard 2D assays produce ambiguous or false-positive results.
Scientifically validated and regulatory-aligned
In early 2025, the European Scientific Advisory Committee (ESAC) validated the RSMN assay as a reliable method for assessing skin-applied substances. This milestone supports the growing integration of non-animal approaches under frameworks such as the EU Cosmetics Regulation, which mandates alternative testing methods.
Looking ahead: skin organoids and the future of NAMs
GenEvolutioN is also pioneering the use of skin organoid models, incorporating multiple cell types—epidermis, dermis, adipocytes, neurons, and hair follicles. These advanced systems allow for individualized genotoxicity assessments and open new avenues for safety profiling of innovative ingredients.
Meet GenEvolutioN at EUROTOX 2025
- Date: September 14th, 2025
- Location: Athens, Greece
- Session T30 – Risk Prediction and Assessment using NAMs
- Poster Title: Interest of the Micronucleus Test on Reconstructed Skin and Skin Organoids for Cosmetic Products
- Authors: Corina Cuceu Petrenci, Theo Lacour, Joana Raposo, Isabelle Mouche — GenEvolutioN
About GenEvolutioN
GenEvolutioN : Your in vitro genotoxicity reference
At GenEvolutioN, we combine scientific rigor with a human touch. As a GLP expert CRO in in vitro toxicology, we leverage the most advanced testing methods and regulatory insight to accelerate safer innovations in cosmetics, pharma, nutrition, medical devices and life sciences. But above all, we see ourselves as your committed partner: we anticipate your needs, adapt our solutions to your challenges, and guide you every step of the way, from risk assessment to market success.
With GenEvolutioN, you gain more than data, you gain confidence, trust, and a true partner in building a healthier future.
